title: [Factors for successful conversion of atrial fibrillation using intravenous injection of pilsicainide hydrochloride].
abstract: OBJECTIVE
  The factors affecting successful conversion of atrial fibrillation using intravenous injection of pilsicainide hydrochloride are unclear. The efficacy of intravenous injection of pilsicainide hydrochloride and the factors affecting successful conversion of symptomatic atrial fibrillation were investigated.
  
  
  METHODS
  Twenty-six patients[21 men, 5 women, 64 +/- 12 years (mean +/- SD)] with electrocardiographically confirmed, symptomatic atrial fibrillation were treated with intravenous injection 1.0 mg/kg of pilsicainide hydrochloride between October 31, 2000 and February 17, 2003. Successful conversion was defined as termination of atrial fibrillation within 30 min of intravenous injection. Before the injection of pilsicainide hydrochloride, blood pressure, conventional electrocardiography, chest radiography, echocardiography and blood examinations were performed. During and after injection of pilsicainide hydrochloride, blood pressure and conventional electrocardiography were monitored. After injection of pilsicainide hydrochloride, blood examinations were performed.
  
  
  RESULTS
  Pharmacological conversion to sinus rhythm was achieved in 7 of 26 patients(27%). The successful conversion group and unsuccessful conversion group showed significant differences in duration of atrial fibrillation(61 +/- 122 vs 12,257 +/- 25,959 hr, p < 0.01), heart rates before injection of pilsicainide (110 +/- 26 vs 87 +/- 26 beats/min, p < 0.05), cardiothoracic ratio(47.8 +/- 2.6% vs 53.5 +/- 5.1%, p < 0.01) and left atrial dimension(38 +/- 7 vs 45 +/- 6 mm, p < 0.05).
  
  
  CONCLUSIONS
  Pilsicainide hydrochloride is effective in patients with atrial fibrillation of short duration with small left atrium and rapid ventricular response.
authors.affiliation: Second Department of Internal Medicine, Yokohama City University School of Medicine, Fukuura 3-9, Kanazawa-ku, Yokohama 236-0004.
authors.forename: Kohei
authors.initials: K
authors.lastname: Matsushita
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Shinichi
authors.initials: S
authors.lastname: Sumita
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Katsumi
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Yohei
authors.initials: Y
authors.lastname: Yamakawa
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ohkusu
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nakagawa
authors.forename: Ichiroh
authors.initials: I
authors.lastname: Nakazawa
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Mochida
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Ebina
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Uchino
authors.forename: Kazuo
authors.initials: K
authors.lastname: Kimura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Umemura
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008012:Lidocaine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
chemical_list: D000889:Anti-Arrhythmia Agents; D008012:Lidocaine; C042288:pilsicainide